Baird served as financial advisor on this offering
AboutBELLUS Health Inc. (“BELLUS” or the “Company”) (TSX: BLU) recently completed a follow-on offering of 36,842,105 shares of common stock at a price to the public of $0.95 per share for total gross proceeds of $35 million. BELLUS intends to use the net proceeds received from the sale of its common stock to fund research and development activities, including but not limited to, BLU-5937’s clinical development, general and administrative expenses, working capital needs and other general corporate purposes.
BELLUS is a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. BELLUS is headquartered in Laval, Quebec, Canada.
CONTACT US TO LEARN MORE
- December 2018
- BELLUS Health Inc.
- Target Location
- North America